30 closest matches · ranked by relevance
Falciparum Malaria
Primary: Percentage of Participants With Parasite Clearance at Day 28 — 97.20 percentage of participants
Uncomplicated Plasmodium Falciparum Malaria
Primary: Percentage of Patients With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28 — 11; 13; 15; 14 Participants
Malaria
Primary: Cure Rates of AQ-13 and Coartem for Uncomplicated Plasmodium Falciparum Malaria in Adult Malian Males. — 28; 31 Participants
Malaria, Falciparum · Malaria, Vivax
Primary: Derived Parasite Reduction Rate at 24 Hours (PPR24) — 1.38; 1.56; 1.71; 1.63 Log10 parasites/24h — p=0.01
Healthy Subjects
Primary: Drug-specific Parasite Reduction Ratio (PRR48) of ACT-451840 Over 48 Hours Using a Standardized Approach — 234.5 Ratio
Acute Malaria
Primary: Cohort A: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Related TEAEs — 9; 0; 1 Participants
Malaria
Primary: Time to Parasite Clearance — 23.63; 44.97; 48.75 Hours
Malaria, Falciparum
Primary: Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitologic Response (ACPR) at Day 28 in the Modified Intent-to-treat…
Plasmodium Falciparum, Malaria
Primary: Infection Rate — 5; 6; 3; 0 Participants
Malaria,Falciparum · Malaria · Malaria Recrudescence
Primary: Emax — 0.201 Maximum clearance rate (1/hour)
Malaria
Primary: Crude Cure Rate on Day 14 — 217; 209; 75; 73 Participants
Acute Uncomplicated Plasmodium Falciparum Malaria
Primary: Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 — 46; 45; 47; 47…
Malaria,Falciparum · Parasitemia · Protozoan Infections
Primary: Incidence and Severity of Observed or Self-reported Adverse Events (AEs) Considered PfSPZ-DVI Challenge Inoculum-related. — 13; 12; 1; 2 Incidence
Falciparum Malaria
Primary: Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28 — 99.2; 98.1 percentage of subjects — p=0.106
Malaria Infection
Primary: Time to Parasitemia Since Negative Blood Smear After Treatment — 62.0; 60.0; NA; NA days
Cure Rate
Primary: 28-day Cure Rate — 63.67 Percentage of participants
Malaria
Primary: Absence of Malaria Parasites in Blood. — 73 Participants
Plasmodium Falciparum Malaria
Primary: PCR-Corrected ACPR at Day 28 — 95; 99; 99 percentage of subjects
Plasmodium Falciparum Malaria
Primary: Parasitological Success (MITT) — 66; 28; 4; 43 participants — p=<0.005
Severe Malaria
Primary: Percentage of Participants Achieving at Least 90% Reduction in Plasmodium Falciparum (P. Falciparum) at 12 Hours — 80.0; 93.0; 39.3 percentage of participants
Malaria
Primary: PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) Rate on Day 28 — 99.5; 99.2 percentage of subjects — p=0.578
Plasmodium Falciparum Infection
Primary: Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 28 (ACPR28) — 80.8; 90.3; 90.9…
P Vivax · Malaria, Vivax
Primary: Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled — 61; 88; 90 participants
Malaria · Falciparum Malaria · Vivax Malaria
Primary: Early Treatment Failure (ETF) — 0; 0 participants
Malaria, Falciparum · Malaria, Vivax
Primary: Crude Adequate Clinical and Parasitological Response (ACPR) — 90; 100 percentage of participants
Uncomplicated Plasmodium Falciparum Malaria
Primary: Polymerase Chain Reaction (PCR) Corrected Adequate Clinical and Parasitological Response (ACPR) — 96.43; 96.67 Percentage of participants
Uncomplicated Plasmodium Falciparum Malaria
Primary: PCR-adjusted ACPR at Day 28 in the PP Population (All Patients) — 70.8; 68.4; 78.6 % ACPR PCR-adjusted
Infections · Vector Borne Diseases · Systemic Inflammatory Response Syndrome
Primary: Emax — 0.35 Maximum clearance rate (1/hour)
Malaria
Primary: Characterize the PK/PD Relationship Between OZ439 and PQP Plasma Concentrations (Cmax) — 0.2582; 0.4145; 0.8829; 0.6835 ng/L
Healthy
Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation of Study Treatment — 13; 6; 5; 3…